{"id":"W3015569704","doi":"10.1136/bjophthalmol-2020-316195","title":"Gene therapy for neovascular age-related macular degeneration: rationale, clinical trials and future directions","year":2020,"lang":"en","type":"review","venue":"British Journal of Ophthalmology","topic":"Retinal Diseases and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology; Moorfields Eye Hospital NHS Foundation Trust; Retina UK; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Moorfields Eye Charity; Wellcome Trust; Wellcome; Fight for Sight; Foundation Fighting Blindness","keywords":"Macular degeneration; Medicine; Clinical trial; Blindness; Genetic enhancement; Bevacizumab; Intensive care medicine; Ophthalmology; Optometry; Surgery; Pathology; Gene; Chemotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001819242,0.0008161009,0.001795951,0.001892405,0.0002838685,0.001494701,0.001093619,0.00190317,0.005034592],"category_scores_gemma":[0.001984423,0.0002789656,0.0008761762,0.00172373,0.0007187524,0.001690937,0.000590994,0.002509579,0.002208041],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007329506,"about_ca_system_score_gemma":0.001704818,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007557963,"about_ca_topic_score_gemma":0.001633499,"domain_scores_codex":[0.9996192,0.00009860294,0.00006584811,0.00005504555,0.000130822,0.0000303513],"domain_scores_gemma":[0.9987229,0.0007987096,0.0001329281,0.00002886725,0.0002462348,0.00007031544],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000167462,0.0001255724,0.0001110416,0.0339416,0.0001132098,0.0001907195,0.000063386,0.0002507491,0.00191585,0.004450282,0.02155503,0.9371151],"study_design_scores_gemma":[0.0001010683,0.0003669751,0.0007089717,0.02124081,0.0003732101,0.001556546,0.00008596252,0.0001492911,0.0006882342,0.00387636,0.9708205,0.00003203524],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006283397,0.9988704,0.00008087925,0.000381298,0.0001426412,0.000008781105,0.00001517967,0.00000430818,0.0004336352],"genre_scores_gemma":[0.0003491636,0.9987393,0.0002050435,0.0003174128,0.0001188334,0.00001487505,0.00001941443,0.000001486822,0.0002344461],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.005034592,"threshold_uncertainty_score":0.01684242,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1706153088601673,"score_gpt":0.4571611162559829,"score_spread":0.2865458073958156,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}